Amivas, LLC is a pharmaceutical company that specializes in the development, commercialization, and distribution of Artesunate, a life-saving medicine for the treatment of severe malaria. With offices in the US, Australia, and Ireland, Amivas manufactures the product in North America, while their partners in Canada, USA, and Europe package and supply it to hospitals and patients in need.
Formed in response to the discontinuation of quinidine gluconate in 2019, Amivas aims to assume responsibility for the manufacture and distribution of Artesunate. With FDA approval of their first commercial product in 2020, Amivas is proud to contribute to the global effort in fighting and eradicating malaria. They have plans for the official launch of Artesunate in the UK and European Union in 2024.
Generated from the website